ATRA ATARA BIOTHERAPEUTICS INC US FDA Inspections 8-K Filing 2025 - Clinical Trials Atara Biotherapeutics, Inc. announced that the FDA lifted the clinical hold on its EBVALLO™ (tabelecleucel) program and granted a Type A meeting to discuss further plans on May 5, 2025. This follows a previous FDA hold placed in January 2025 regarding the program.Get access to all SEC 8-K filings of the ATARA BIOTHERAPEUTICS INC